Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Receivables (2024 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Receivables for 2 consecutive years, with $882612.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables changed N/A year-over-year to $882612.0, compared with a TTM value of $882612.0 through Oct 2025, changed N/A, and an annual FY2025 reading of $1.4 million, up 209.36% over the prior year.
  • Receivables was $882612.0 for Q4 2025 at VitaNova Life Sciences, down from $1.0 million in the prior quarter.
  • Across five years, Receivables topped out at $1.4 million in Q2 2025 and bottomed at $54018.0 in Q1 2025.